Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gap Junctions01:37

Gap Junctions

57.3K
Multicellular organisms employ a variety of ways for cells to communicate with each other. Gap junctions are specialized proteins that form pores between neighboring cells in animals, connecting the cytoplasm between the two, and allowing for the exchange of molecules and ions. They are found in a wide range of invertebrate and vertebrate species, mediate numerous functions including cell differentiation and development, and are associated with numerous human diseases, including cardiac and...
57.3K
Gap Junctions01:27

Gap Junctions

9.8K
The cytoplasm of adjacent animal cells can exchange small molecules, ions, and secondary messengers via the communication channels which form the gap junctions. These junctions comprise a few hundred to thousands of molecular channels, each made of two halves, called the connexon hemichannel. A connexon is a hexamer of six transmembrane connexin proteins, which assemble radially, thus forming a pore or channel in the center. One connexon hemichannel docks with a corresponding connexon on the...
9.8K
Viral Recombination00:57

Viral Recombination

25.2K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.2K
Viral Structure00:56

Viral Structure

74.8K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2 testing uptake and its determinants in six ethnic groups living in Amsterdam, the Netherlands: a registry-based study within the HELIUS cohort.

European journal of public health·2026
Same author

High-dose corticosteroids are associated with higher mortality in patients with COVID-19 ARDS: Results from a nationwide observational study.

Journal of critical care·2026
Same author

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Dissemination of ESBL-producing <i>Escherichia coli</i> and carriage in the community worldwide: epidemiology, transmission pathways, molecular insights, and practical aspects.

Clinical microbiology reviews·2026
Same author

Major ECG abnormalities and risk of incident cardiovascular disease in people with HIV compared to people without HIV.

AIDS (London, England)·2026
Same author

Health-related quality of life in well-treated people with HIV and comparators over an 8-year period: a longitudinal analysis from the prospective AGEhIV cohort study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Feb 12, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K

Research gaps in viral hepatitis.

Anders Boyd1,2, Léa Duchesne1, Karine Lacombe3,4

  • 1INSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.

Journal of the International AIDS Society
|April 11, 2018
PubMed
Summary

Global elimination of hepatitis B (HBV) and hepatitis C (HCV) requires improved vaccination strategies, wider testing, and expanded access to antiviral therapies, especially for key populations. Further research is needed to bridge the gap in reaching these populations and achieving elimination goals.

Keywords:
antiviralseradicationhepatitis B virushepatitis C viruspublic healthtesting

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Related Experiment Videos

Last Updated: Feb 12, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.9K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Hepatology

Background:

  • The World Health Organization targets global elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030.
  • Effective treatments and vaccines exist, but challenges remain in achieving widespread coverage and access.

Purpose of the Study:

  • To discuss essential public health approaches for HBV and HCV elimination.
  • To identify research gaps in vaccination, testing, and treatment strategies.

Main Methods:

  • The study broadly discusses three public health approaches: vaccination, diagnostics, and antiviral therapy.
  • It highlights the need for further evidence on implementation and effectiveness in key populations.

Main Results:

  • HBV vaccination coverage is suboptimal in certain regions, and a prophylactic HCV vaccine is not readily available.
  • Point-of-care tests and expanded antiviral therapy access are crucial for increasing awareness and reducing transmission.
  • Novel HBV treatments are in early development, and real-world evidence is needed for expanded treatment eligibility.

Conclusions:

  • Effective tools exist, but reaching key populations and establishing necessary infrastructure are major research gaps.
  • Continuously adapted research is essential to prioritize and achieve viral hepatitis elimination goals.